MDT

86.04

-0.05%↓

120.64

-0.83%↓

VEEV

169.54

+0.98%↑

HQY

86.06

+0.15%↑

NEOG

9.56

+0.63%↑

MDT

86.04

-0.05%↓

120.64

-0.83%↓

VEEV

169.54

+0.98%↑

HQY

86.06

+0.15%↑

NEOG

9.56

+0.63%↑

MDT

86.04

-0.05%↓

120.64

-0.83%↓

VEEV

169.54

+0.98%↑

HQY

86.06

+0.15%↑

NEOG

9.56

+0.63%↑

MDT

86.04

-0.05%↓

120.64

-0.83%↓

VEEV

169.54

+0.98%↑

HQY

86.06

+0.15%↑

NEOG

9.56

+0.63%↑

MDT

86.04

-0.05%↓

120.64

-0.83%↓

VEEV

169.54

+0.98%↑

HQY

86.06

+0.15%↑

NEOG

9.56

+0.63%↑

Strona główna・Stock List・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Open

SectorHealthcare

4.81 -0.21

Buy Sell

Overview

Share price change

24h

Current

Min

4.71

Max

5.06

Key metrics
By Trading Economics
Income	-12M -27M
Sales	-5.3M 663K
P/E Sector Avg	22.5 63.808
Profit margin	-3,998.492
Employees	69
EBITDA	-13M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+183.61% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-195M 949M
Previous open	5.02
Previous close	4.81

News Sentiment

By Acuity

29%

71%

64 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

0.7658 / N/A Support & Resistance

CytomX Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 kwi 2026, 23:48 UTC

Major News Events

Crude Oil, Refined Product Prices Moving Higher Amid Renewed Tensions in Strait of Hormuz -- OPIS

19 kwi 2026, 23:36 UTC

Major News Events

NAB Raises Provisions as Australian Banks Face Iran Risks -- Update

19 kwi 2026, 22:47 UTC

Major News Events

National Australia Bank Adds $215 Million in Iran-Driven Credit Provisions

19 kwi 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

19 kwi 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

19 kwi 2026, 23:49 UTC

Market Talk

Major News Events

Gold, Silver Decline Amid Renewed Inflation Concerns -- Market Talk

19 kwi 2026, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

19 kwi 2026, 23:38 UTC

Major News Events

U.A.E. Asks U.S. About a Wartime Financial Lifeline -- Update

19 kwi 2026, 23:36 UTC

Market Talk

Major News Events

Oil Climbs on Renewed Tensions Over Strait of Hormuz -- Market Talk

19 kwi 2026, 23:12 UTC

Major News Events

Spot Gold Falls 1.2%, Spot Silver Drops 1.6% on Renewed Middle East Tensions

19 kwi 2026, 23:10 UTC

Major News Events

Front-Month Brent Crude Oil Futures Rise 5.8% to $95.64 per Barrel

19 kwi 2026, 23:09 UTC

Major News Events

Front-Month WTI Crude Oil Futures Climb 7.2% to $89.86 per Barrel

19 kwi 2026, 23:08 UTC

Major News Events

Front-Month Crude Oil Futures Climb on Renewed Tensions Over Strait of Hormuz

19 kwi 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Nears Deal for Cancer Biotech -- WSJ

19 kwi 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Announcement Could Come As Soon As Monday, Sources Say -- WSJ

19 kwi 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Deal Expected to Be Worth Over $2B Plus Additional Milestones, Sources Say -- WSJ

19 kwi 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Nears Deal for Kelonia Therapeutics, Sources Say -- WSJ

19 kwi 2026, 20:03 UTC

Major News Events

U.A.E. Central Bank Governor Khaled Mohamed Balama Raised Swap Idea With Treasury Secretary Scott Bessent in Washington -- WSJ

19 kwi 2026, 20:03 UTC

Major News Events

Emiratis Portrayed Swap Proposal as Precautionary and Preliminary in Case Iran War Drags On -- WSJ

19 kwi 2026, 20:03 UTC

Major News Events

The U.A.E. Has Opened Talks with U.S. for Currency Swap -- WSJ

19 kwi 2026, 20:03 UTC

Major News Events

U.A.E. Asks U.S. for a Wartime Financial Lifeline -- WSJ

18 kwi 2026, 01:00 UTC

Major News Events

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

17 kwi 2026, 22:58 UTC

Earnings

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 kwi 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 kwi 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 kwi 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17 kwi 2026, 20:52 UTC

Earnings

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 kwi 2026, 20:50 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

17 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 kwi 2026, 20:29 UTC

Earnings

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

Peer Comparison

Price change

CytomX Therapeutics Inc Forecast

Price Target

By TipRanks

183.61% upside

12 Months Forecast

Average 13.67 USD 183.61%

High 17 USD

Low 11 USD

Based on 9 Wall Street analysts offering 12 month price targets forCytomX Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to CytomX Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.7658 / N/ASupport & Resistance

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

64 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.